10 results about "Urokinase" patented technology

This invention belongs to the field of urea preparation technology and discloses a large-particle urea, composed of the following raw materials in a specific ratio: a 50% concentration of dilute urine solvent, a urokinase activity inhibitor, and a pigment, in a ratio of 100:6:5. This solution, through the careful design of the 50% concentration of dilute urine solvent, the urokinase activity inhibitor, and the pigment, enhances the soil dissolution rate and utilization rate. The addition of the urokinase activity inhibitor effectively inhibits the rapid hydrolysis of urea, reduces ammonia nitrogen loss, improves nitrogen utilization, mitigates negative environmental impacts, and contributes to soil ecological balance. The use of large-particle morphology and strict moisture control technology ensures the product's moisture resistance and storage stability, extending its shelf life. During production, the temperature is precisely controlled at 30℃, which avoids urine crystallization, ensures the full dissolution of the urokinase activity inhibitor, avoids odors generated at high temperatures, reduces environmental pollution, and improves the product's environmental friendliness.

This invention discloses a fusion protein targeting the urokinase-type plasminogen activator receptor and its application in the field of anti-aging. The fusion protein is composed of a hepatocyte growth factor active domain and a humanized anti-uPAR single-domain antibody linked by a flexible linker peptide, and its specific amino acid sequence is SEQ ID NO:3. This fusion protein can specifically bind to uPAR, which is highly expressed on the surface of senescent cells, with intramolar affinity, achieving targeted delivery of the hepatocyte growth factor active domain. In vitro experiments have demonstrated that this protein can significantly reverse the aging phenotype of human fibroblasts, effectively reduce aging-related β-galactosidase activity, p16INK4a protein expression, and interleukin-6 secretion, and promote cell proliferation. In a rapidly aging mouse model, this protein can systematically improve age-related physiological functional decline. The fusion protein of this invention achieves specific targeting and efficient treatment of senescent cells, providing a new solution for the development of anti-aging drugs.

Disclosed herein, are peptides that bind urokinase-type plasminogen activator receptors. The peptides may comprise amino acid sequences of IPPWEAPK (SEQ ID NO: 1), DLAQCQTPTQAAPPTPVSPR (SEQ ID NO: 2), or LHVPLMPAQPAPPK (SEQ ID NO: 3), or retro-inverso amino acid sequences of the above enumerated sequences. Also described herein, are methods of administering compounds comprising peptides that bind urokinase-type plasminogen activator receptors to subjects for the treatment of ovarian cancer and improving wound closure.

This invention relates to the field of biotechnology, specifically to a TruC-T cell that secretes and expresses IL-7 and PF4 to enhance anti-tumor activity and targets uPAR, and its application. Interleukin-7 (IL-7) can effectively promote the development, survival, and proliferation of T cells, while platelet factor 4 (PF4 / CXCL4) can regulate the immune response and chemotactically attract leukocytes to specific sites; the synergistic effect of the two can enhance the anti-tumor function and persistence of T cells. Meanwhile, urokinase-type plasminogen activator receptor (uPAR) is highly expressed in various solid tumors and hematological malignancies, making it an ideal target for tumor therapy; TruC-T cells targeting uPAR can precisely act on tumor tissue, and combined with the immune-enhancing effects of IL-7 and PF4, can significantly improve the efficacy of anti-tumor immune responses, prolong the duration of therapeutic effects, and reduce tumor recurrence.

The application discloses an engineered exosome targeting human urokinase-type plasminogen activator receptor uPAR and a preparation method and application thereof. Firstly, a high-affinity anti-human uPAR single-domain antibody VHH is prepared; then, a human umbilical cord mesenchymal stem cell engineering cell line expressing a VHH-PTGFRN fusion protein is constructed, and the engineered exosome is prepared and purified by combining three-dimensional hypoxic culture, chemical induction and size-exclusion chromatography technology. The engineered exosome comprises four comparative samples, wherein the core sample Exo^(VHH / miR) can simultaneously display the anti-uPAR VHH on the membrane surface to realize targeted delivery and enrich miR-193b-3p in the chamber to realize gene silencing, and the synergistic effect of the two can efficiently remove the uPAR high-expression senescent cells and inhibit the senescence-associated secretory phenotype SASP. The engineered exosome has the advantages of standardized preparation process, high yield and high purity, strong targeting, excellent curative effect and good safety, and can be used for preparing a treatment preparation for anti-aging and aging-related diseases, and has important clinical application value.

The invention discloses preparation and application of macrophage targeting nanoparticles entrapped with a cell burial function accelerant. The medicine for enhancing the intercellular function of the macrophages is a liver X receptor stimulant, and the liver X receptor stimulant comprises at least one of T0901317, GW3965, Ouabagenin and LXR-623. The surface of the targeting nanoparticle is coated with a macrophage cell membrane, and meanwhile, a urokinase type plasminogen activator receptor (uPAR) targeting ligand is modified. The nanoparticle can be efficiently accumulated at an inflammatory focus part by utilizing a macrophage cell membrane, and the modified targeting ligand is used for targeting the macrophage with damaged cell burial function, so that the cell burial function of the macrophage is enhanced, the polarization of the macrophage to an anti-inflammatory phenotype is promoted, the release of anti-inflammatory and proinflammatory cytokines is regulated, and the anti-inflammatory effect of the nanoparticle is improved. And finally, the inflammatory microenvironment of a focus part is regulated and controlled, so that a good effect of treating autoimmune diseases is achieved.

This invention belongs to the field of biotechnology and provides an antibody or its antigen-binding fragment against the urokinase plasminogen activator receptor and its applications. The antibody or its antigen-binding fragment of this invention comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region includes heavy chain complementarity-determining regions HCDR1, HCDR2, and HCDR3, and the light chain variable region includes light chain complementarity-determining regions LCDR1, LCDR2, and LCDR3. The antibody or its antigen-binding fragment of this invention can bind with high affinity to human uPAR protein and can induce an anti-tumor specific immune response.

This invention discloses a detection kit for residual urokinase protein, its preparation method, and its application. The detection kit includes a capture antibody and a detection antibody. The capture antibody includes a polyclonal antibody against residual urokinase protein, and the detection antibody includes a biotin-labeled polyclonal antibody against residual urokinase protein. The polyclonal antibody against residual urokinase protein is obtained by repeatedly immunizing animals with residual urokinase protein as an immunogen. The residual urokinase protein is obtained by further purifying crude human urinary kininogenase by adsorption and removal of urokinase using an affinity column with an anti-urokinase monoclonal antibody. This invention fills the gap in the detection of residual drug proteins in urinary sources. It has high specificity, an antibody coverage rate of over 70%, and a method quantification limit of approximately 4 ng / ml. It has a low detection limit and high sensitivity for residual urokinase protein, requires no expensive instruments, and is easy to operate.

This invention discloses a method for preparing liquid urokinase, specifically including the main steps of ion exchange chromatography, first-stage affinity chromatography, stabilization treatment, second-stage affinity chromatography, and ultrafiltration concentration. Through optimized design of the separation and purification process, combining ion exchange chromatography, affinity chromatography, stabilization treatment, and ultrafiltration concentration, the overall quality and stability of the urokinase product are synergistically optimized, giving it the advantage of long-term stability in liquid form and eliminating the need for an additional freeze-drying stabilization process. The liquid product facilitates precise metering, feeding, and transfer during downstream formulation production, avoiding material loss during production, simplifying subsequent production processes, and improving the quality and process control of related products. Simultaneously, optimizations were also made in certain parts of the process; precise control of the stabilization treatment and ultrafiltration concentration effectively ensures the quality of the liquid urokinase product.